Journals / Haseki Tıp Bülteni / 2020 / Cilt: 58 - Sayı: 5

Papilledema: Could It Be an Important Clinical Sign of Leptomeningeal Metastasis?

Papilödem: Leptomeninjiyal Metastazın Önemli Klinik İşareti Olabilir mi?

Pages
441–446
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Presence of papilledema is thought to contribute to the diagnosis since the evaluation of intracranial in LM patients is a non-invasive evaluation method.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Leptomeningeal metastasis (LM), which can be seen in all types of cancer, is a rare condition with poor prognosis.
📊
Key Findings & Data:Methods: Sixteen patients who received the diagnosis of LM between 2018 and 2020 were included in the study retrospectively.
💡
Conclusion & Impact:Presence of papilledema is thought to contribute to the diagnosis since the evaluation of intracranial in LM patients is a non-invasive evaluation method.
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Leptomeningeal metastasis (LM), which can be seen in all types of cancer, is a rare condition with poor prognosis. Diagnosis and treatment are important components of the management of the disease. We aimed to reveal clues for early diagnosis by examining the clinical and laboratory features of LM. Methods: Sixteen patients who received the diagnosis of LM between 2018 and 2020 were included in the study retrospectively. The cerebrospinal fluid (CSF) samples and cranial magnetic resonance imaging of the patients were examined. In addition, the patients were divided into two groups according to the presence of papilledema. Results: The mean age of the patients was 49 (19-73) and 37.5% were women. The most common histological tumor type was adenocarcinoma. The most common clinical finding was multiple cranial neuropathy. The mean time to the diagnosis of LM was 20 months. Eleven of the 16 patients had solid tumors, five had hematological malignancies. Nine patients had papilledema. Headache was significantly more common in the group with papilledema (p=0.01). The average lifespan after the diagnosis of LM was 8 months (1-48 months). Malignant cells were detected in the CSF cytology of four patients (30%). Conclusion: LM is a condition with poor prognosis and difficult to diagnose in oncology patients, despite all tests being performed under appropriate conditions. Presence of papilledema is thought to contribute to the diagnosis since the evaluation of intracranial in LM patients is a non-invasive evaluation method.

Özet

Amaç: Leptomeninjiyal metastaz (LM) tüm kanser tiplerinde izlenebilen nadir ancak kötü prognozlu bir klinik tablodur. Tanı, tedavi ve prognoz hastalığı yönetmekte önemli süreçlerdendir. Bu amaçla LM klinik ve laboratuvar özelliklerinin inceleyerek erken tanı için ipuçları ortaya koyabilmeyi amaçladık. Yöntemler: Çalışmaya retrospektif olarak 2018-2020 yılları arasında Leptomeninjal tanısı almış 16 hasta dahil edildi. Hastaların beyin omurilik sıvısı (BOS) örnekleri ve kranial magnetik rezonans görüntüleme tetkikleri incelendi. Ayrıca hastalar papilödem varlığına göre iki gruba ayrıldı. İstatistiksel analiz uygulandı. Bulgular: Hastaların yaş ortalaması 49 (19-73), %37,5’i kadındı. En sık izlenen histolojik tümör tipi adeno karsinom idi. En sık izlenen klinik bulgu multipl kranial nöropati idi. LM tanısına kadar geçen süre ortalama 20 ay (1-112 ay) idi. On altı hastanın 11’inde solid tümör, beşinde hematolojik malignite mevcuttu. Dokuz hastada papilödem mevcuttu. Baş ağrısı yakınması papilödem olan grupta istatistiksel olarak anlamlı şekilde daha yüksek iken (p=0,01) diğer klinik bulgularda anlamlı farklılık yoktu. LM sonrası ortalama yaşam süresi 8 aydı (1-48 ay). Dört hastanın BOS sitolojisinde malign hücreler tespit edildi (%30). Sonuç: LM onkoloji hastalarında kötü prognozlu ve tüm tetkiklerin uygun koşullarda yapılmasına karşın tanısı zor konabilen bir durumdur. Papilödem varlığı LM hastalarında noninvaziv değerlendirme yöntemlerinden biri olarak tanıya katkı sağlayabileceği düşünülmüştür

🔖

Cite This Article

DÜZ, Ö. A., OLMUŞÇELİK, O., ÇADIRCI, F. (2020). Papilledema: Could It Be an Important Clinical Sign of Leptomeningeal Metastasis?. Haseki Tıp Bülteni, Cilt: 58 - Sayı: 5, 441–446. https://ajindex.com/articles/267774

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Taillibert S, Chamberlain MC. Leptomeningeal metastasis. Handb Clin Neurol 2018;149:169-204
  2. Mack F, Baumert BG, Schäfer N, et al. Therapy of leptomeninjial metastasis in solid tumors. Cancer Treat Rev 2016;43:83-91
  3. Groves MD. The pathogenesis of neoplastic meningitis. Curr Oncol Rep 2003;5:15-23
  4. Seute T, Leffers P, ten Velde GP, Twijnstra A. Leptomeninjial metastases from small cell lung carcinoma. Cancer 2005;104:1700-5
  5. Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer. Cancer 1978;42:283-6
  6. Aroney RS, Dalley DN, Chan WK, Bell DR, Levi JA. Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 1981;71:26-32
  7. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978;42:660-8
  8. Yokote A, Kawamoto T, Namioka T, Moteki Y, Kawamata T. Diagnosis of leptomeninjial metastasis without a history of malignancy in the absence of cerebrospinal fluid abnormalities. Clin Neurol Neurosurg 2014;119:88-90
  9. Thakkar JP, Kumthekar P, Dixit KS, Stupp R, Lukas RV. Leptomeningeal metastasis from solid tumors. J Neurol Sci 2020;411:116706
  10. Bönig L, Möhn N, Ahlbrecht J, et al. Leptomeningeal metastasis: the role of cerebrospinal fluid diagnostics. Front Neurol 2019;10:839
  11. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeninjial metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-72
  12. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeninjial metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990;9:225-9
  13. Rhun EL, Weller M, Brandsma D, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeninjial metastasis from solid tumours. Ann Oncol 2017;28(Suppl 4):iv84-99
  14. Leal T, Chang JE, Mehta M, Robins HI. Leptomeninjial metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev 2011;7:319-27
  15. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998;82:733-9
  16. Chamberlain MC. Leptomeninjial metastasis. Semin Neurol 2010;30:236-44
  17. Kolmel HW. Cytology of neoplastic meningosis. J Neurooncol 1998;38:121-5
  18. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeninjial metastases in the MRI